# BIOMILQ

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/biomilq

- Industry: Biotechnology
- Headquarters: Durham, US
- Website: www.biomilq.com
- Total disclosed funding: $21M
- Latest round: Series A (Oct 20, 2021)
- Investors on record: 7

## About

BIOMILQ Inc. is an innovative biotechnology company focused on developing lab-grown human milk alternatives, providing a new infant feeding option that mimics the nutritional profile of breast milk.Founded in 2019 and headquartered in Durham, US, BIOMILQ Inc. specializes in creating human milk through biotechnology. The company has completed three funding rounds, with the most recent being a Series A in October 2021, raising USD 21.00 mn led by Novo Holdings. Co-founders Leila Strickland and Michelle Hiring spearhead the company's mission to revolutionize infant nutrition.BIOMILQ Inc. is dedicated to developing lab-grown human milk, providing a novel infant feeding option designed to closely replicate the nutritional composition of breast milk. This innovative product targets parents seeking alternatives to traditional infant feeding methods, ensuring a safe and nutritious option for infants. The primary users include healthcare providers, infant formula manufacturers, and parents looking for healthier feeding options for their children.The revenue model for BIOMILQ Inc. is primarily based on partnerships and collaborations with infant formula manufacturers and healthcare providers. The company aims to establish agreements that will allow for the distribution of its lab-grown human milk products, generating revenue through licensing and direct sales once the product is commercialized. This model is designed to cater to a range of clients in the healthcare and infant nutrition sectors.Following the Series A funding round in October 2021, BIOMILQ Inc. plans to utilize the USD 21.00 mn raised to accelerate the development of its pioneering mammary biotechnology. The company aims to bring its lab-grown human milk product to market, enhancing infant nutrition options by late 2023. Additionally, BIOMILQ is exploring opportunities to collaborate with healthcare providers and enter new geographical markets, including Europe and Asia-Pacific, by 2024.

## Funding rounds

- Series A, Oct 20, 2021, $21M — Novo Holdings, Breakthrough Energy Ventures, Digitalis Ventures, Gaingels, Spero Ventures, Blue Horizon, GreenGen Ventures

## Investors

- Novo Holdings — Series A
- Breakthrough Energy Ventures (https://capitalatlas.ai/funds/breakthrough-energy-ventures) — Series A
- Digitalis Ventures (https://capitalatlas.ai/funds/digitalis-ventures) — Series A
- Gaingels (https://capitalatlas.ai/funds/gaingels) — Series A
- Spero Ventures (https://capitalatlas.ai/funds/spero-ventures) — Series A
- Blue Horizon (https://capitalatlas.ai/funds/blue-horizon) — Series A
- GreenGen Ventures (https://capitalatlas.ai/funds/greengen-ventures) — Series A